Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries

Given the relatively recent introduction of burosumab in the management of X-linked hypophosphatemia (XLH), there is limited real-world data to guide its use in clinical practice. As a group of European physicians experienced with burosumab treatment in clinical practice, we convened with the object...

Descripción completa

Detalles Bibliográficos
Autores principales: Mughal, M. Zulf, Baroncelli, Giampiero I., de Lucas-Collantes, Carmen, Linglart, Agnès, Magnolato, Andrea, Raimann, Adalbert, Santos, Fernando, Schnabel, Dirk, Shaw, Nick, Nilsson, Ola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928183/
https://www.ncbi.nlm.nih.gov/pubmed/36798486
http://dx.doi.org/10.3389/fendo.2022.1034580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928183/
https://www.ncbi.nlm.nih.gov/pubmed/36798486
http://dx.doi.org/10.3389/fendo.2022.1034580

Ejemplares similares